Literature DB >> 6185700

Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling.

J S Meyer, G Sufrin, S A Martin.   

Abstract

The thymidine labeling index (TLI) was measured in vitro in the epithelium and stroma of benign prostate glands and seminal vesicles and in the epithelium of prostatic adenocarcinomas. The mean epithelial TLI of normal peripheral (posterior) prostatic zone was 0.12 per cent, and that of the normal central (deep) zone was 0.11 per cent. Mean normal stromal TLI's were 0.08 per cent and 0.06 per cent, respectively. The mean TLI of epithelium in nodular hyperplasia was 0.31 per cent, which differs significantly from normal epithelium (p less than 0.05), and the mean stromal TLI was also increased (0.16 per cent, p less than 0.1). The mean TLI of prostatic adenocarcinomas was 0.90 per cent (range 0.14 to 3.90 per cent) which was significantly higher than for either normal epithelium (p less than 0.001) or epithelium of nodular hyperplasia (p less than 0.05). Trends of increasing TLI with increasing histologic grades and increasing nuclear size and numbers of nucleoli were not significant. The data support participation of both epithelial and stromal proliferation in nodular hyperplasia, and indicate a low basal proliferative rate in normal prostatic glands. The low TLI's of prostatic adenocarcinomas relative to other malignancies are consistent with their frequently slowly progressive course. The very low proliferative rate of seminal vesicular epithelium (mean TLI 0.02 per cent) may account for the rarity of seminal vesicular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6185700     DOI: 10.1016/s0022-5347(17)53506-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.

Authors:  R R Berges; Y Furuya; L Remington; H F English; T Jacks; J T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

2.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

3.  Implication of cell kinetic changes during the progression of human prostatic cancer.

Authors:  R R Berges; J Vukanovic; J I Epstein; M CarMichel; L Cisek; D E Johnson; R W Veltri; P C Walsh; J T Isaacs
Journal:  Clin Cancer Res       Date:  1995-05       Impact factor: 12.531

4.  Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA.

Authors:  P J Hepburn; E Glynne-Jones; L Goddard; J M Gee; M E Harper
Journal:  Histochem J       Date:  1995-03

5.  The value of prognostic factors in prostatic cancer.

Authors:  J Schubert; S Kowalik
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

6.  Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages.

Authors:  Jaromir Gumulec; Michaela Fojtu; Martina Raudenska; Marketa Sztalmachova; Anna Skotakova; Jana Vlachova; Sylvie Skalickova; Lukas Nejdl; Pavel Kopel; Lucia Knopfova; Vojtech Adam; Rene Kizek; Marie Stiborova; Petr Babula; Michal Masarik
Journal:  Int J Mol Sci       Date:  2014-12-11       Impact factor: 5.923

Review 7.  The role of prostate-specific antigen velocity in prostate cancer early detection.

Authors:  S R Potter; H B Carter
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

8.  Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.

Authors:  Christoph Zenzmaier; Natalie Sampson; Eugen Plas; Peter Berger
Journal:  Prostate       Date:  2013-06-14       Impact factor: 4.104

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.